Utilizing the molecular gateway: the path to personalized cancer management.
about
Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancerSuppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma.Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinicSimulated annealing based algorithm for identifying mutated driver pathways in cancerBiomarkers of HIV-associated Cancer.Inferring causal genomic alterations in breast cancer using gene expression data.Polymorphisms and a haplotype in heparanase gene associations with the progression and prognosis of gastric cancer in a northern Chinese population.Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapyA multiplex two-color real-time PCR method for quality-controlled molecular diagnostic testing of FFPE samples.New aspects in the differential diagnosis and therapy of bladder pain syndrome/interstitial cystitisIntegrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer.A novel inhibitor of DNA polymerase beta enhances the ability of temozolomide to impair the growth of colon cancer cells.(13)C breath tests in personalized medicine: fiction or reality?Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.Deciphering oncogenic drivers: from single genes to integrated pathways.Efficient methods for identifying mutated driver pathways in cancer.Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression.Current status and future prospects of biomarkers in the diagnosis of hepatocellular carcinoma.CONCORD biomarker prediction for novel drug introduction to different cancer types.Versatile immunoassays based on isomagnetophoresis.
P2860
Q28541215-8C806956-FC25-45BE-8DEF-200CEAA846BBQ30009202-12BC4B74-20E6-4A29-AF49-E38A3B4A9091Q30438089-370C30AB-1E5E-4926-BDD7-980A3A92D526Q30498812-20A2E103-EFDF-4F73-BD26-D7DDF26E03D5Q33757602-6A8F86AA-BF2F-42B0-A350-030B257A2C86Q33856851-4E3EFF17-877C-4CBA-BF7E-1A2460734847Q33977659-7763C026-FF5B-4D95-8647-665FC2CDB852Q34140460-910EC434-B541-46A5-B5BE-22AA8076449FQ34256150-343E27C1-8B0D-4202-A299-0660D8283552Q35107220-84934BE3-9E9D-4BAC-9F72-66DD906A2CCFQ35418701-8EC8F559-EF18-48B1-A6B9-C1111DD4E247Q35561695-18873A28-9A38-409A-A7C9-E7961C8244AEQ37485063-5B95C6FC-5E91-4C62-BE00-30AD7399F853Q37628680-45518137-5E64-4093-9114-E4D815594D0DQ37638755-28952E20-872D-4C85-A79C-BF4B92A7D156Q38265995-814E1BB0-C8C3-45B5-99AC-AB8D8B46277BQ44542966-A5C0A97E-C367-4F1B-A191-F094A878EE16Q45720150-2A56140C-CDE3-42EE-9447-FE6D79DC65AFQ47920503-4A6202BB-01EE-4567-811C-7A190E340EB4Q50128212-C540F04C-E8A8-4ACB-82AC-BADF9F6EE5A0Q51548952-F2FEC5F2-832A-4800-8B6F-34DAFC913196
P2860
Utilizing the molecular gateway: the path to personalized cancer management.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Utilizing the molecular gateway: the path to personalized cancer management.
@ast
Utilizing the molecular gateway: the path to personalized cancer management.
@en
type
label
Utilizing the molecular gateway: the path to personalized cancer management.
@ast
Utilizing the molecular gateway: the path to personalized cancer management.
@en
prefLabel
Utilizing the molecular gateway: the path to personalized cancer management.
@ast
Utilizing the molecular gateway: the path to personalized cancer management.
@en
P2093
P2860
P1433
P1476
Utilizing the molecular gateway: the path to personalized cancer management.
@en
P2093
Dan Theodorescu
Jonathan B Overdevest
P2860
P304
P356
10.1373/CLINCHEM.2008.118554
P407
P577
2009-02-26T00:00:00Z